Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Substituted Aminoacetamides as Novel Leads for Malaria Treatment.

Norcross NR, Wilson C, Baragaña B, Hallyburton I, Osuna-Cabello M, Norval S, Riley J, Fletcher D, Sinden R, Delves M, Ruecker A, Duffy S, Meister S, Antonova-Koch Y, Crespo B, de Cózar C, Sanz LM, Gamo FJ, Avery VM, Frearson JA, Gray DW, Fairlamb AH, Winzeler EA, Waterson D, Campbell SF, Willis PA, Read KD, Gilbert IH.

ChemMedChem. 2019 Jul 17;14(14):1329-1335. doi: 10.1002/cmdc.201900329. Epub 2019 Jul 3.

PMID:
31188540
2.

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.

Wyllie S, Brand S, Thomas M, De Rycker M, Chung CW, Pena I, Bingham RP, Bueren-Calabuig JA, Cantizani J, Cebrian D, Craggs PD, Ferguson L, Goswami P, Hobrath J, Howe J, Jeacock L, Ko EJ, Korczynska J, MacLean L, Manthri S, Martinez MS, Mata-Cantero L, Moniz S, Nühs A, Osuna-Cabello M, Pinto E, Riley J, Robinson S, Rowland P, Simeons FRC, Shishikura Y, Spinks D, Stojanovski L, Thomas J, Thompson S, Viayna Gaza E, Wall RJ, Zuccotto F, Horn D, Ferguson MAJ, Fairlamb AH, Fiandor JM, Martin J, Gray DW, Miles TJ, Gilbert IH, Read KD, Marco M, Wyatt PG.

Proc Natl Acad Sci U S A. 2019 May 7;116(19):9318-9323. doi: 10.1073/pnas.1820175116. Epub 2019 Apr 8.

3.

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis.

Baragaña B, Forte B, Choi R, Nakazawa Hewitt S, Bueren-Calabuig JA, Pisco JP, Peet C, Dranow DM, Robinson DA, Jansen C, Norcross NR, Vinayak S, Anderson M, Brooks CF, Cooper CA, Damerow S, Delves M, Dowers K, Duffy J, Edwards TE, Hallyburton I, Horst BG, Hulverson MA, Ferguson L, Jiménez-Díaz MB, Jumani RS, Lorimer DD, Love MS, Maher S, Matthews H, McNamara CW, Miller P, O'Neill S, Ojo KK, Osuna-Cabello M, Pinto E, Post J, Riley J, Rottmann M, Sanz LM, Scullion P, Sharma A, Shepherd SM, Shishikura Y, Simeons FRC, Stebbins EE, Stojanovski L, Straschil U, Tamaki FK, Tamjar J, Torrie LS, Vantaux A, Witkowski B, Wittlin S, Yogavel M, Zuccotto F, Angulo-Barturen I, Sinden R, Baum J, Gamo FJ, Mäser P, Kyle DE, Winzeler EA, Myler PJ, Wyatt PG, Floyd D, Matthews D, Sharma A, Striepen B, Huston CD, Gray DW, Fairlamb AH, Pisliakov AV, Walpole C, Read KD, Van Voorhis WC, Gilbert IH.

Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7015-7020. doi: 10.1073/pnas.1814685116. Epub 2019 Mar 20.

4.

Nongenotoxic 3-Nitroimidazo[1,2-a]pyridines Are NTR1 Substrates That Display Potent in Vitro Antileishmanial Activity.

Fersing C, Basmaciyan L, Boudot C, Pedron J, Hutter S, Cohen A, Castera-Ducros C, Primas N, Laget M, Casanova M, Bourgeade-Delmas S, Piednoel M, Sournia-Saquet A, Belle Mbou V, Courtioux B, Boutet-Robinet É, Since M, Milne R, Wyllie S, Fairlamb AH, Valentin A, Rathelot P, Verhaeghe P, Vanelle P, Azas N.

ACS Med Chem Lett. 2018 Dec 19;10(1):34-39. doi: 10.1021/acsmedchemlett.8b00347. eCollection 2019 Jan 10.

PMID:
30655943
5.

Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani.

Corpas-Lopez V, Moniz S, Thomas M, Wall RJ, Torrie LS, Zander-Dinse D, Tinti M, Brand S, Stojanovski L, Manthri S, Hallyburton I, Zuccotto F, Wyatt PG, De Rycker M, Horn D, Ferguson MAJ, Clos J, Read KD, Fairlamb AH, Gilbert IH, Wyllie S.

ACS Infect Dis. 2019 Jan 11;5(1):111-122. doi: 10.1021/acsinfecdis.8b00226. Epub 2018 Nov 12.

6.

Development of Chemical Proteomics for the Folateome and Analysis of the Kinetoplastid Folateome.

Webster LA, Thomas M, Urbaniak M, Wyllie S, Ong H, Tinti M, Fairlamb AH, Boesche M, Ghidelli-Disse S, Drewes G, Gilbert IH.

ACS Infect Dis. 2018 Oct 12;4(10):1475-1486. doi: 10.1021/acsinfecdis.8b00097. Epub 2018 Sep 28.

7.

Antitrypanosomatid Pharmacomodulation at Position 3 of the 8-Nitroquinolin-2(1H)-one Scaffold Using Palladium-Catalysed Cross-Coupling Reactions.

Pedron J, Boudot C, Bourgeade-Delmas S, Sournia-Saquet A, Paloque L, Rastegari M, Abdoulaye M, El-Kashef H, Bonduelle C, Pratviel G, Wyllie S, Fairlamb AH, Courtioux B, Verhaeghe P, Valentin A.

ChemMedChem. 2018 Oct 22;13(20):2217-2228. doi: 10.1002/cmdc.201800456. Epub 2018 Sep 17.

PMID:
30221468
8.

Author Correction: Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.

Field MC, Horn D, Fairlamb AH, Ferguson MAJ, Gray DW, Read KD, De Rycker M, Torrie LS, Wyatt PG, Wyllie S, Gilbert IH.

Nat Rev Microbiol. 2018 Nov;16(11):714. doi: 10.1038/s41579-018-0085-1.

PMID:
30206344
9.

Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis.

Wyllie S, Thomas M, Patterson S, Crouch S, De Rycker M, Lowe R, Gresham S, Urbaniak MD, Otto TD, Stojanovski L, Simeons FRC, Manthri S, MacLean LM, Zuccotto F, Homeyer N, Pflaumer H, Boesche M, Sastry L, Connolly P, Albrecht S, Berriman M, Drewes G, Gray DW, Ghidelli-Disse S, Dixon S, Fiandor JM, Wyatt PG, Ferguson MAJ, Fairlamb AH, Miles TJ, Read KD, Gilbert IH.

Nature. 2018 Aug;560(7717):192-197. doi: 10.1038/s41586-018-0356-z. Epub 2018 Jul 25.

10.

A role for trypanosomatid aldo-keto reductases in methylglyoxal, prostaglandin and isoprostane metabolism.

Roberts AJ, Dunne J, Scullion P, Norval S, Fairlamb AH.

Biochem J. 2018 Aug 30;475(16):2593-2610. doi: 10.1042/BCJ20180232.

11.

Antitrypanosomal 8-Hydroxy-Naphthyridines Are Chelators of Divalent Transition Metals.

Wall RJ, Moniz S, Thomas MG, Norval S, Ko EJ, Marco M, Miles TJ, Gilbert IH, Horn D, Fairlamb AH, Wyllie S.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00235-18. doi: 10.1128/AAC.00235-18. Print 2018 Aug.

12.

Characterisation of a putative glutamate 5-kinase from Leishmania donovani.

Sienkiewicz N, Ong HB, Fairlamb AH.

FEBS J. 2018 Jul;285(14):2662-2678. doi: 10.1111/febs.14511. Epub 2018 May 27.

13.

Melarsoprol Resistance in African Trypanosomiasis.

Fairlamb AH, Horn D.

Trends Parasitol. 2018 Jun;34(6):481-492. doi: 10.1016/j.pt.2018.04.002. Epub 2018 Apr 25. Review.

14.

Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis.

Patterson S, Fairlamb AH.

Curr Med Chem. 2019;26(23):4454-4475. doi: 10.2174/0929867325666180426164352. Review.

PMID:
29701144
15.

Screening a protein kinase inhibitor library against Plasmodium falciparum.

Hallyburton I, Grimaldi R, Woodland A, Baragaña B, Luksch T, Spinks D, James D, Leroy D, Waterson D, Fairlamb AH, Wyatt PG, Gilbert IH, Frearson JA.

Malar J. 2017 Nov 7;16(1):446. doi: 10.1186/s12936-017-2085-4.

16.

Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani.

Torrie LS, Brand S, Robinson DA, Ko EJ, Stojanovski L, Simeons FRC, Wyllie S, Thomas J, Ellis L, Osuna-Cabello M, Epemolu O, Nühs A, Riley J, MacLean L, Manthri S, Read KD, Gilbert IH, Fairlamb AH, De Rycker M.

ACS Infect Dis. 2017 Oct 13;3(10):718-727. doi: 10.1021/acsinfecdis.7b00047. Epub 2017 Oct 2.

17.

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.

Field MC, Horn D, Fairlamb AH, Ferguson MAJ, Gray DW, Read KD, De Rycker M, Torrie LS, Wyatt PG, Wyllie S, Gilbert IH.

Nat Rev Microbiol. 2017 Jul;15(7):447. doi: 10.1038/nrmicro.2017.69. Epub 2017 Jun 5. No abstract available.

PMID:
28579611
18.

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.

Field MC, Horn D, Fairlamb AH, Ferguson MA, Gray DW, Read KD, De Rycker M, Torrie LS, Wyatt PG, Wyllie S, Gilbert IH.

Nat Rev Microbiol. 2017 Feb 27;15(4):217-231. doi: 10.1038/nrmicro.2016.193. [Epub ahead of print] Review. Erratum in: Nat Rev Microbiol. 2017 Jul;15(7):447. Nat Rev Microbiol. 2018 Nov;16(11):714.

19.

Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania.

Wyllie S, Roberts AJ, Norval S, Patterson S, Foth BJ, Berriman M, Read KD, Fairlamb AH.

PLoS Pathog. 2016 Nov 3;12(11):e1005971. doi: 10.1371/journal.ppat.1005971. eCollection 2016 Nov.

20.

Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase.

Hewitt SN, Dranow DM, Horst BG, Abendroth JA, Forte B, Hallyburton I, Jansen C, Baragaña B, Choi R, Rivas KL, Hulverson MA, Dumais M, Edwards TE, Lorimer DD, Fairlamb AH, Gray DW, Read KD, Lehane AM, Kirk K, Myler PJ, Wernimont A, Walpole C, Stacy R, Barrett LK, Gilbert IH, Van Voorhis WC.

ACS Infect Dis. 2017 Jan 13;3(1):34-44. doi: 10.1021/acsinfecdis.6b00078. Epub 2016 Nov 16.

21.

The Role of Folate Transport in Antifolate Drug Action in Trypanosoma brucei.

Dewar S, Sienkiewicz N, Ong HB, Wall RJ, Horn D, Fairlamb AH.

J Biol Chem. 2016 Nov 18;291(47):24768-24778. Epub 2016 Oct 4.

22.

Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.

Baragaña B, Norcross NR, Wilson C, Porzelle A, Hallyburton I, Grimaldi R, Osuna-Cabello M, Norval S, Riley J, Stojanovski L, Simeons FR, Wyatt PG, Delves MJ, Meister S, Duffy S, Avery VM, Winzeler EA, Sinden RE, Wittlin S, Frearson JA, Gray DW, Fairlamb AH, Waterson D, Campbell SF, Willis P, Read KD, Gilbert IH.

J Med Chem. 2016 Nov 10;59(21):9672-9685. Epub 2016 Sep 10.

23.

Drug resistance in eukaryotic microorganisms.

Fairlamb AH, Gow NA, Matthews KR, Waters AP.

Nat Microbiol. 2016 Jun 24;1(7):16092. doi: 10.1038/nmicrobiol.2016.92. Review.

24.

The N-myristoylome of Trypanosoma cruzi.

Roberts AJ, Fairlamb AH.

Sci Rep. 2016 Aug 5;6:31078. doi: 10.1038/srep31078.

25.

Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials.

Norcross NR, Baragaña B, Wilson C, Hallyburton I, Osuna-Cabello M, Norval S, Riley J, Stojanovski L, Simeons FR, Porzelle A, Grimaldi R, Wittlin S, Duffy S, Avery VM, Meister S, Sanz L, Jiménez-Díaz B, Angulo-Barturen I, Ferrer S, Martínez MS, Gamo FJ, Frearson JA, Gray DW, Fairlamb AH, Winzeler EA, Waterson D, Campbell SF, Willis P, Read KD, Gilbert IH.

J Med Chem. 2016 Jul 14;59(13):6101-20. doi: 10.1021/acs.jmedchem.6b00028. Epub 2016 Jun 17.

26.

Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis.

Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G, Ruecker A, Upton LM, Abraham TS, Almeida MJ, Pradhan A, Porzelle A, Martínez MS, Bolscher JM, Woodland A, Luksch T, Norval S, Zuccotto F, Thomas J, Simeons F, Stojanovski L, Osuna-Cabello M, Brock PM, Churcher TS, Sala KA, Zakutansky SE, Jiménez-Díaz MB, Sanz LM, Riley J, Basak R, Campbell M, Avery VM, Sauerwein RW, Dechering KJ, Noviyanti R, Campo B, Frearson JA, Angulo-Barturen I, Ferrer-Bazaga S, Gamo FJ, Wyatt PG, Leroy D, Siegl P, Delves MJ, Kyle DE, Wittlin S, Marfurt J, Price RN, Sinden RE, Winzeler EA, Charman SA, Bebrevska L, Gray DW, Campbell S, Fairlamb AH, Willis PA, Rayner JC, Fidock DA, Read KD, Gilbert IH.

Nature. 2016 Sep 1;537(7618):122. doi: 10.1038/nature18280. Epub 2016 May 25. No abstract available.

27.

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis.

Patterson S, Wyllie S, Norval S, Stojanovski L, Simeons FR, Auer JL, Osuna-Cabello M, Read KD, Fairlamb AH.

Elife. 2016 May 24;5. pii: e09744. doi: 10.7554/eLife.09744.

28.

Trypanosoma brucei DHFR-TS Revisited: Characterisation of a Bifunctional and Highly Unstable Recombinant Dihydrofolate Reductase-Thymidylate Synthase.

Gibson MW, Dewar S, Ong HB, Sienkiewicz N, Fairlamb AH.

PLoS Negl Trop Dis. 2016 May 13;10(5):e0004714. doi: 10.1371/journal.pntd.0004714. eCollection 2016 May.

29.

Open Lab as a source of hits and leads against tuberculosis, malaria and kinetoplastid diseases.

Ballell L, Strange M, Cammack N, Fairlamb AH, Borysiewicz L.

Nat Rev Drug Discov. 2016 Apr;15(4):292. doi: 10.1038/nrd.2016.51. Epub 2016 Mar 29. No abstract available.

PMID:
27020099
30.

Genomic and Proteomic Studies on the Mode of Action of Oxaboroles against the African Trypanosome.

Jones DC, Foth BJ, Urbaniak MD, Patterson S, Ong HB, Berriman M, Fairlamb AH.

PLoS Negl Trop Dis. 2015 Dec 18;9(12):e0004299. doi: 10.1371/journal.pntd.0004299. eCollection 2015 Dec.

31.

Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomes.

Bruhn DF, Wyllie S, Rodríguez-Cortés A, Carrillo AK, Rakesh, Guy RK, Fairlamb AH, Lee RE.

J Antimicrob Chemother. 2016 Apr;71(4):956-63. doi: 10.1093/jac/dkv417. Epub 2015 Dec 18.

32.

Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei.

Wyllie S, Foth BJ, Kelner A, Sokolova AY, Berriman M, Fairlamb AH.

J Antimicrob Chemother. 2016 Mar;71(3):625-34. doi: 10.1093/jac/dkv376. Epub 2015 Nov 17.

33.

A novel multiple-stage antimalarial agent that inhibits protein synthesis.

Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G, Ruecker A, Upton LM, Abraham TS, Almeida MJ, Pradhan A, Porzelle A, Luksch T, Martínez MS, Luksch T, Bolscher JM, Woodland A, Norval S, Zuccotto F, Thomas J, Simeons F, Stojanovski L, Osuna-Cabello M, Brock PM, Churcher TS, Sala KA, Zakutansky SE, Jiménez-Díaz MB, Sanz LM, Riley J, Basak R, Campbell M, Avery VM, Sauerwein RW, Dechering KJ, Noviyanti R, Campo B, Frearson JA, Angulo-Barturen I, Ferrer-Bazaga S, Gamo FJ, Wyatt PG, Leroy D, Siegl P, Delves MJ, Kyle DE, Wittlin S, Marfurt J, Price RN, Sinden RE, Winzeler EA, Charman SA, Bebrevska L, Gray DW, Campbell S, Fairlamb AH, Willis PA, Rayner JC, Fidock DA, Read KD, Gilbert IH.

Nature. 2015 Jun 18;522(7556):315-20. doi: 10.1038/nature14451. Erratum in: Nature. 2016 Sep 1;537(7618):122.

34.

Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study.

Perry MR, Prajapati VK, Menten J, Raab A, Feldmann J, Chakraborti D, Sundar S, Fairlamb AH, Boelaert M, Picado A.

PLoS Negl Trop Dis. 2015 Mar 2;9(3):e0003518. doi: 10.1371/journal.pntd.0003518. eCollection 2015 Mar.

35.

Synthesis, biological profiling and mechanistic studies of 4-aminoquinoline-based heterodimeric compounds with dual trypanocidal-antiplasmodial activity.

Sola I, Castellà S, Viayna E, Galdeano C, Taylor MC, Gbedema SY, Pérez B, Clos MV, Jones DC, Fairlamb AH, Wright CW, Kelly JM, Muñoz-Torrero D.

Bioorg Med Chem. 2015 Aug 15;23(16):5156-67. doi: 10.1016/j.bmc.2015.01.031. Epub 2015 Jan 24.

PMID:
25678015
36.

Lead optimization of a pyrazole sulfonamide series of Trypanosoma brucei N-myristoyltransferase inhibitors: identification and evaluation of CNS penetrant compounds as potential treatments for stage 2 human African trypanosomiasis.

Brand S, Norcross NR, Thompson S, Harrison JR, Smith VC, Robinson DA, Torrie LS, McElroy SP, Hallyburton I, Norval S, Scullion P, Stojanovski L, Simeons FR, van Aalten D, Frearson JA, Brenk R, Fairlamb AH, Ferguson MA, Wyatt PG, Gilbert IH, Read KD.

J Med Chem. 2014 Dec 11;57(23):9855-69. doi: 10.1021/jm500809c. Epub 2014 Nov 20.

37.

Homoserine and quorum-sensing acyl homoserine lactones as alternative sources of threonine: a potential role for homoserine kinase in insect-stage Trypanosoma brucei.

Ong HB, Lee WS, Patterson S, Wyllie S, Fairlamb AH.

Mol Microbiol. 2015 Jan;95(1):143-56. doi: 10.1111/mmi.12853. Epub 2014 Nov 25.

38.

TrypanoCyc: a community-led biochemical pathways database for Trypanosoma brucei.

Shameer S, Logan-Klumpler FJ, Vinson F, Cottret L, Merlet B, Achcar F, Boshart M, Berriman M, Breitling R, Bringaud F, Bütikofer P, Cattanach AM, Bannerman-Chukualim B, Creek DJ, Crouch K, de Koning HP, Denise H, Ebikeme C, Fairlamb AH, Ferguson MA, Ginger ML, Hertz-Fowler C, Kerkhoven EJ, Mäser P, Michels PA, Nayak A, Nes DW, Nolan DP, Olsen C, Silva-Franco F, Smith TK, Taylor MC, Tielens AG, Urbaniak MD, van Hellemond JJ, Vincent IM, Wilkinson SR, Wyllie S, Opperdoes FR, Barrett MP, Jourdan F.

Nucleic Acids Res. 2015 Jan;43(Database issue):D637-44. doi: 10.1093/nar/gku944. Epub 2014 Oct 9.

39.

Norspermidine is not a self-produced trigger for biofilm disassembly.

Hobley L, Kim SH, Maezato Y, Wyllie S, Fairlamb AH, Stanley-Wall NR, Michael AJ.

Cell. 2014 Feb 13;156(4):844-54. doi: 10.1016/j.cell.2014.01.012.

40.

Biochemical and genetic characterization of Trypanosoma cruzi N-myristoyltransferase.

Roberts AJ, Torrie LS, Wyllie S, Fairlamb AH.

Biochem J. 2014 Apr 15;459(2):323-32. doi: 10.1042/BJ20131033.

41.

Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis.

Perry MR, Wyllie S, Raab A, Feldmann J, Fairlamb AH.

Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19932-7. doi: 10.1073/pnas.1311535110. Epub 2013 Oct 28.

42.

Trypanosoma brucei (UMP synthase null mutants) are avirulent in mice, but recover virulence upon prolonged culture in vitro while retaining pyrimidine auxotrophy.

Ong HB, Sienkiewicz N, Wyllie S, Patterson S, Fairlamb AH.

Mol Microbiol. 2013 Oct;90(2):443-55. doi: 10.1111/mmi.12376. Epub 2013 Sep 9.

43.

The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.

Patterson S, Wyllie S, Stojanovski L, Perry MR, Simeons FR, Norval S, Osuna-Cabello M, De Rycker M, Read KD, Fairlamb AH.

Antimicrob Agents Chemother. 2013 Oct;57(10):4699-706. doi: 10.1128/AAC.00722-13. Epub 2013 Jul 15.

44.

Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.

De Rycker M, Hallyburton I, Thomas J, Campbell L, Wyllie S, Joshi D, Cameron S, Gilbert IH, Wyatt PG, Frearson JA, Fairlamb AH, Gray DW.

Antimicrob Agents Chemother. 2013 Jul;57(7):2913-22. doi: 10.1128/AAC.02398-12. Epub 2013 Apr 9. Erratum in: Antimicrob Agents Chemother. 2014 Dec;58(12):7622.

45.

Allosteric activation of trypanosomatid deoxyhypusine synthase by a catalytically dead paralog.

Nguyen S, Jones DC, Wyllie S, Fairlamb AH, Phillips MA.

J Biol Chem. 2013 May 24;288(21):15256-67. doi: 10.1074/jbc.M113.461137. Epub 2013 Mar 21.

46.

A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes.

De Rycker M, O'Neill S, Joshi D, Campbell L, Gray DW, Fairlamb AH.

PLoS Negl Trop Dis. 2012;6(11):e1932. doi: 10.1371/journal.pntd.0001932. Epub 2012 Nov 29.

47.

Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation.

Wyllie S, Patterson S, Fairlamb AH.

Antimicrob Agents Chemother. 2013 Feb;57(2):901-6. doi: 10.1128/AAC.01788-12. Epub 2012 Dec 3.

48.

Chemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosome.

Jones DC, Alphey MS, Wyllie S, Fairlamb AH.

Mol Microbiol. 2012 Oct;86(1):51-64. doi: 10.1111/j.1365-2958.2012.08189.x. Epub 2012 Aug 16.

49.

Infectious disease: Genomics decodes drug action.

Fairlamb AH.

Nature. 2012 Feb 8;482(7384):167-9. doi: 10.1038/482167a. No abstract available.

PMID:
22318598
50.

The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.

Wyllie S, Patterson S, Stojanovski L, Simeons FR, Norval S, Kime R, Read KD, Fairlamb AH.

Sci Transl Med. 2012 Feb 1;4(119):119re1. doi: 10.1126/scitranslmed.3003326.

Supplemental Content

Loading ...
Support Center